In brief
  • Patent cover runs to 2032 and 2036 while shortage-era compounding rules have closed
  • Salt forms, added B vitamins and altered dosing sit outside the studied products
  • Poison center calls rose sharply as regulators acted on claims and marketing

The FDA started sending warning letters to compounders making unsupported statements about copied GLP-1 medicines, Stanford Medicine reported, after shortage permissions that began in 2022 came to an end. Generic semaglutide remains blocked by patents until at least 2032, while tirzepatide patents run until 2036, and the FTC shows a health claims matter titled TruHeight, In the Matter of, dated July 15, 2026.

GLP-1 means glucagon-like peptide-1, an intestinal hormone involved in glucose control and hunger signaling. Drugs that turn on its receptor imitate that signal. Approved semaglutide brands are Ozempic, Wegovy and Rybelsus, and approved tirzepatide brands are Mounjaro and Zepbound.

Copied preparations lack FDA approval matching the branded medicines. During 2024, at peak use, almost 1 in 3 Americans on a GLP-1 drug reported obtaining it through a compounding pharmacy. Patented GLP-1 products carry list prices above $1,000 each month, and physicians describe the cost and availability pressures pushing patients toward copies as genuine.

Chemistry often shifts without clear notice on the label. Certain compounders dispense salt versions including semaglutide sodium, forms that FDA has not approved and that lack proof of safety and efficacy in people. Many preparations include vitamin B12 plus extras such as B6, niacinamide, glycine or carnitine, none with established benefit for diabetes control or weight reduction. A 2026 study reported that tirzepatide mixed with B12 can join chemically into a separate molecule absent from the FDA-approved medicine, work that Eli Lilly independently repeated.

Dose accuracy adds further exposure. FDA has highlighted episodes in which people drawing from multidose vials injected 10 to 20 times the intended quantity in error. Some compounding pharmacies market sublingual drops or dissolving tablets containing semaglutide or tirzepatide, presentations never evaluated in clinical trials. Calls to U.S. poison control centers tied to injected weight-loss drugs have grown by more than 15-fold since 2019.

Telehealth marketing drew a separate enforcement result. The FTC approved a final order against telehealth company NextMed and principals Robert Epstein and Frank Leonardo concerning GLP-1 weight-loss programs. In its July 2025 complaint, the FTC alleged that NextMed sold weight-loss programs with undisclosed costs, unsubstantiated weight-loss claims, fake testimonials and distorted reviews. The order orders $150,000 in payment, expected to be used for consumer refunds, and demands competent and reliable evidence behind statements about average or typical results.

Marina Basina, MD, clinical professor in endocrinology, gerontology and metabolism, said compounded drugs used with GLP 1s without medical supervision pose clear risk and can produce serious clinical consequences

Written by

Victoria Hawkins

Victoria looks after the brands Half Life works with and makes sure every sponsored page is labelled and dose-checked like the rest. She spent six years in regulatory affairs at a supplement maker, so she knows exactly what a label is allowed to say.

More from Victoria Hawkins →